This inventor holds 42 USPTO granted patents and 50 published patent applications, plus 8 CIPO patents and 18 EPO patents, primarily in CNS Edema Treatments. Top assignees: Biogen Chesapeake LLC, Remedy Pharmaceuticals, Inc., Critical Care Diagnostics, Inc.. Active years: 2011-2026.
Company Filing History:
13 out of 13 
12 out of 13 
9 out of 35 
Years Active: 2011-2026
Areas of Expertise:
Title: Sven Jacobson: Innovator in Neurological Treatments
Introduction: Sven Jacobson, a prominent inventor based in New York, NY, has made significant contributions to the field of medical treatments, particularly in addressing neurological conditions. With an impressive portfolio of 33 patents, Jacobson has dedicated his career to finding innovative solutions for complex health issues, especially those related to dementia and amyotrophic lateral sclerosis (ALS).
Latest Patents: Among his latest patents, Jacobson's work on "Methods of treating agitation and other dementia-associated behavioral symptoms" stands out. This innovation is rooted in the discovery that rho kinase inhibitors, especially fasudil, can effectively treat agitation and anxiety in dementia patients, particularly those suffering from Alzheimer's disease. The treatment with fasudil has demonstrated remarkable improvements in agitation, significantly surpassing the results seen with other potential therapeutic agents. Another noteworthy invention is his "Method of treating amyotrophic lateral sclerosis," which details how administering oral fasudil at a dosage of 180-240 mg per day can lead to a 25-50% reduction in the average decline of sporadic ALS patients over at least three months, as measured using the revised ALS Functional Rating Scale.
Career Highlights: Over the years, Sven Jacobson has worked with prominent companies in the pharmaceutical and diagnostics sectors, including Biogen Chesapeake LLC and Critical Care Diagnostics, Inc. His dedication to innovation is evident in his extensive research and development efforts, aimed at improving patient outcomes.
Collaborations: Throughout his career, Jacobson has collaborated with esteemed colleagues and professionals in the field. Notable coworkers include James V. Snider and Thomas MacAllister, with whom he has shared insights and strategies to push the boundaries of medical research and development.
Conclusion: Sven Jacobson continues to be a leading figure in the innovation of treatments for neurological disorders. His commitment to research and his groundbreaking patents have the potential to significantly improve the quality of life for individuals suffering from conditions such as Alzheimer's disease and ALS. As the field of medical science evolves, Jacobson’s work exemplifies the impact of dedicated inventors in the quest for effective therapies.